Literature DB >> 10985756

Gene expression and serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins in a case of non-islet cell tumour hypoglycaemia.

R I Holt1, J D Teale, J S Jones, J D Quin, A M McGregor, J P Miell.   

Abstract

We describe a case of non-islet cell tumour hypoglycaemia (NICTH) associated with a renal cell carcinoma. Serum insulin-like growth factors (IGFs) (including IGF-II E peptide), IGF-binding proteins (IGFBPs), insulin and C-peptide were measured before and after surgical removal of the tumour. IGFBPs were visualized by Western ligand blotting. Preoperatively 'big' IGF-II and IGFBP-2 levels were raised. IGF-I, IGFBP-1 and IGFBP-3 were low, while insulin, C-peptide and GH were undetectable. These changes were reversed by 2 days postoperatively. Protease assays showed little IGFBP-3 protease activity preoperatively. Preoperatively, neutral chromatography demonstrated most of the immunoassayable IGFBP-3 in a high molecular weight form with a small amount of IGF-II. Most of the IGF-II and big IGF-II eluted in lower molecular weight forms. Postoperative samples showed a shift in IGF-II which became increasingly associated with IGFBP-3 in both low and high molecular weight complexes. By Northern blotting, expression of all species of IGF-II mRNA in the tumour was 10-fold greater than in normal human liver. The tumour did not express IGFBP-1 or IGFBP-2. IGFBP-3 was expressed in small amounts, while the expression of IGFBP-4 was two-fold higher than in liver. In conclusion, we have confirmed high levels of big IGF-II and IGFBP-2 in NICTH, changes which are reversed postoperatively. The IGF-II is derived from the tumour which overexpresses these genes but IGFBP-2 probably arises from extratumour upregulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10985756     DOI: 10.1016/s1096-6374(98)80297-9

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  6 in total

1.  A rare cause of hypoglycaemia.

Authors:  Pinaki Dutta; Anil Bhansali; Santosh Kumar; P Jayaprakash; Uma Nahar
Journal:  BMJ Case Rep       Date:  2009-12-07

2.  When a nephrectomy cures hypoglycaemia.

Authors:  Aonghus O'Loughlin; Frank Waldron-Lynch; Kevin Christopher Cronin; Sean Dinneen; John Lee; Damian Griffin; Mary Casey; N Nusrat; Syed Jaffrey; Timothy O'Brien; Fidelma Dunne
Journal:  BMJ Case Rep       Date:  2009-05-17

Review 3.  Management of non-islet-cell tumor hypoglycemia: a clinical review.

Authors:  Timothy W Bodnar; Maria J Acevedo; Massimo Pietropaolo
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

4.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.

Authors:  Nathan E Hoffmann; Yuri Sheinin; Christine M Lohse; Alexander S Parker; Bradley C Leibovich; Zhong Jiang; Eugene D Kwon
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

5.  Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor.

Authors:  Satoshi Takeuchi; Tomohiro Goda; Jun Taguchi; Yuichi Douhata; Rio Honma; Shin Ariga; Yoshihito Ohhara; Yasushi Shimizu; Ichiro Kinoshita; Izumi Fukuda; Yoji Nagashima; Hirotoshi Akita
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

6.  Doege-Potter Syndrome: A Presumptive Case of Metastatic Hemangiopericytoma with Persistent Hypoglycemia in a 27-Year-Old Male.

Authors:  Von Lovel Zarra; Kenny Jun Demegillo; May Uyking-Naranjo; Ahmad Domado
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.